Skip to main content
Caplight Logo









Shasqi

Shasqi

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.shasqi.com/

Last Round

Grant

Dec 8, 2021

Est. Valuation

$1.79M

Total Funding Raised

$64.03M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Shasqi is a biotechnology company that develops cancer therapeutics using its proprietary CAPAC (Click Activated Protodrugs Against Cancer) platform, which utilizes in vivo click chemistry for targeted drug delivery to tumor sites to enhance efficacy and minimize systemic toxicity.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

click chemistrytargeted cancer therapyclick activated protodrugsCAPchemotherapy deliveryprecision oncologytumor-localized activationdrug delivery platformbiotech R&Dcancer drug discoverysite-specific therapychemo-boostingclinical-stage biotechtherapeutic index

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shasqi Comparables

Compare Shasqi with similar companies based on industry and business-model similarity.

Shasqi comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tagworks Pharmaceuticals
88%
Avacta Group
75%
CytomX Therapeutics
74%

Shasqi Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 8, 2021
Series BNov 11, 2021
GrantApr 27, 2021
Series AOct 31, 2019
SeedJul 20, 2016
Accelerator
Jan 1, 2015

Key People

Founding team and executive leadership

José M. Mejía Oneto

Founder And CEO

Founding Team

Shasqi Investors

Notable investors and investment history

Shasqi investors
InvestorRounds
National Cancer InstituteGrant
Y CombinatorSeed, Accelerator, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors increased 58% MoM.

  • Nov 11, 2021

    Raised $50M with participation from Bill Rieflin and Juan Jaen.

Shasqi Filings

Explore SEC and related filing metadata, where available.

Shasqi filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Shasqi's valuation, stock price, and market status.

Is Shasqi a public or private company?

Shasqi is a private company.

What is the current stock price of Shasqi?

Shasqi is a private company with no public stock price. No recent secondary market data is available.

How much is Shasqi worth (valuation)?

Valuation information for Shasqi is not publicly available.

Can I buy Shasqi stock?

Shasqi shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Shasqi's last funding round?

Shasqi's most recent funding round was Grant on December 8, 2021.

Who are the main investors in Shasqi?

Key investors in Shasqi include Y Combinator.

Will Shasqi IPO soon?

No public IPO plans have been announced for Shasqi.

How can I track Shasqi secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Shasqi's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range19
Year Founded2015
Last FundingDec 8, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?